Medicenna Therapeutics will present interim results from its Phase 1/2 ABILITY-1 trial of MDNA11, the only long-acting 'beta-enhanced not-alpha' IL-2 super-agonist in clinical development for advanced solid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.